← All trials
NCT02630108
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2015
- Primary completion
- Dec 1, 2017
- Completion date
- Apr 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 280
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fudan UniversityLead sponsor
- Fudan UniversityOverall official - principal investigator
- Changhai HospitalCollaborator
- Eastern Hepatobiliary Surgery HospitalCollaborator
- Shengjing HospitalCollaborator
- Jilin Provincial Tumor HospitalCollaborator
- Fudan UniversityCollaborator
- Henan Medical UniversityCollaborator
- Central South UniversityCollaborator
- Anhui Medical UniversityCollaborator
- University of Electronic Science and Technology of ChinaCollaborator
- Shantou UniversityCollaborator
- Southern Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Zhejiang UniversityCollaborator
- Shandong Tumor HospitalCollaborator
- Anhui College of Traditional Chinese MedicineCollaborator
- Harbin Medical UniversityCollaborator
- LanZhou UniversityCollaborator
- Xinjiang Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.